Pluri Biotech

Pluri has successfully completed the first phase of its program with Resbiomed, demonstrating its ability to translate complex, placenta-derived biomaterials into scalable, reproducible manufacturing processes.
Executed through PluriCDMO™, the program highlights Pluri’s strengths in advanced bioprocessing, process definition, and manufacturing readiness for collagen-rich and ECM-based products.
This milestone reinforces PluriCDMO’s position as a trusted CDMO partner for companies developing next-generation biologics and advanced biomaterials.

https://www.manilatimes.net/2026/01/22/tmt-newswire/globenewswire/pluri-successfully-completes-first-phase-of-resbiomed-program-for-placenta-derived-collagen-rich-biomaterials/2263691

Pluri Successfully Completes First Phase of Resbiomed Program for Placenta-Derived Collagen-Rich Biomaterials HAIFA, Israel, Jan. 22, 2026 (GLOBE NEWSWIRE) -- Pluri, Inc. ('Pluri”, the 'Company”, 'we” or 'us”) (Nasdaq, TASE: PLUR), a biotechnology company leveraging its proprietary platform for cell-based solutions through a collaborative network of ventures, today announced the completion of the fi...